Christoph Reinhard

Christoph Reinhard, PhD, is a life science consultant, leader in oncology translational research and former senior director of translational sciences oncology at Eli Lilly and Company. His work is focused on oncology drug development at biotech and pharmaceutical companies with a particular emphasis on target qualification and discovery of strategies enabling individualized treatment. Dr Reinhard’s special interests evolved out of large-scale genomic studies of gastrointestinal patient tumors that demonstrated the need for mechanism-based target selection and biomarker-guided drug development. Dr Reinhard is currently engaged as chief scientific officer of CELLphenomics GmbH, which aims to enable individualized treatment of patients based on organoid cultures of their tumors. He also previously served as an associate director of oncology at Novartis Institutes for BioMedical Research.